Amgen Inc. $AMGN Stake Lessened by Atlas Private Wealth Advisors

Key Points

• Atlas Private Wealth Advisors cut its Amgen stake by 35.4% in the third quarter, selling 5,075 shares and retaining 9,254 shares valued at approximately $3.9 million.
• Other institutional investors increased their holdings, and institutions and hedge funds collectively own 76.5% of Amgen’s stock.
• Amgen reported quarterly EPS of $6.29, beating estimates by $0.67, and revenue rose 9.5% year over year to $10.05 billion. The company also pays a $2.52 quarterly dividend, while analysts maintain a consensus “Hold” rating with an average price target of $389.71.

Atlas Private Wealth Advisors lessened its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 35.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 9,254 shares of the medical research company's stock after selling 5,075 shares during the quarter. Amgen accounts for approximately 0.8% of Atlas Private Wealth Advisors' portfolio, making the stock its 25th biggest position. Atlas Private Wealth Advisors' holdings in Amgen were worth $3,901,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Signaturefd LLC raised its holdings in shares of Amgen by 5.5% in the 3rd quarter. Signaturefd LLC now owns 14,861 shares of the medical research company's stock valued at $6,264,000 after purchasing an additional 775 shares in the last quarter. Forbes Financial Planning Inc. grew its stake in shares of Amgen by 80.6% during the third quarter. Forbes Financial Planning Inc. now owns 616 shares of the medical research company's stock worth $260,000 after purchasing an additional 275 shares in the last quarter. McGuire Investment Group LLC increased its holdings in Amgen by 4.6% in the third quarter. McGuire Investment Group LLC now owns 13,791 shares of the medical research company's stock valued at $5,813,000 after buying an additional 607 shares during the last quarter. Simplicity Wealth LLC increased its holdings in Amgen by 16.8% in the third quarter. Simplicity Wealth LLC now owns 12,305 shares of the medical research company's stock valued at $5,187,000 after buying an additional 1,766 shares during the last quarter. Finally, Carolina Wealth Advisors LLC increased its holdings in Amgen by 1.2% in the third quarter. Carolina Wealth Advisors LLC now owns 13,167 shares of the medical research company's stock valued at $5,550,000 after buying an additional 157 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of AMGN opened at $439.26 on Friday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $450.98. The stock has a market cap of $237.48 billion, a PE ratio of 27.30, a price-to-earnings-growth ratio of 3.22 and a beta of 0.41. The firm has a fifty day moving average price of $417.70 and a 200 day moving average price of $377.83.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business's quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.96 EPS for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen's payout ratio is presently 62.65%.

Analyst Ratings Changes

A number of research firms have weighed in on AMGN. Royal Bank Of Canada raised their price target on Amgen from $400.00 to $430.00 and gave the company an "outperform" rating in a research note on Thursday, October 8th. Guggenheim lowered their price objective on Amgen from $388.00 to $378.00 and set a "neutral" rating for the company in a research report on Tuesday, October 13th. TD Cowen increased their price objective on Amgen from $420.00 to $452.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Mizuho increased their price objective on Amgen from $303.00 to $352.00 and gave the company a "neutral" rating in a report on Tuesday, August 18th. Finally, Wall Street Zen raised Amgen from a "hold" rating to a "buy" rating in a research report on Sunday, October 18th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Amgen currently has an average rating of "Hold" and an average price target of $389.71.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained its Buy rating and a $457 price target, implying continued confidence in Amgen’s earnings outlook, cash generation and pipeline. Piper Sandler Keeps Buy Rating on Amgen
• Positive Sentiment: Pipeline progress provides a potential catalyst: Amgen’s bemarituzumab study in gastric cancer has reached the Phase 3 finish line. While the report does not provide final efficacy or regulatory results, completion of the trial could eventually support a new oncology growth opportunity. Amgen Bemarituzumab Trial Update
• Neutral Sentiment: Tezspire update offers limited immediate clarity: Amgen reported results for Tezspire, but the available headline does not specify the clinical findings or their commercial implications. Investors will need additional detail to assess the impact on sales expectations. Amgen Reports Tezspire Results
• Negative Sentiment: Patent-cliff and dividend concerns are resurfacing: Coverage questions whether Amgen can protect its dividend when major products lose patent protection. The issue may weigh on the stock because investors are evaluating whether future cash flow can support both shareholder returns and replacement growth. Amgen Dividend and Patent Cliff Risks

Insider Transactions at Amgen

In related news, SVP Nancy Grygiel sold 2,970 shares of the company's stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company's stock, valued at $2,951,854.40. This represents a 28.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. This represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 6,222 shares of company stock valued at $2,540,926. Insiders own 0.85% of the company's stock.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.